Therapies are currently available for relapsing-remitting MS, secondary progressive MS and progressive relapsing MS.
目前有针对复发-缓解型，继发-进展型，与进展-复发型多发硬化症的治疗方案。
RNFL loss was most evident in the temporal quadrant, where significant reduction was seen in primary progressive MS versus controls and in secondary versus primary progressive MS.
视网膜神经纤维层的缺失在颞象限最为明显，在原发性进行性多发性硬化与继发性进行性多发性硬化相比时降低显著。
The mean RNFL thickness and macular volume were significantly reduced in secondary progressive MS, but not in primary progressive MS when compared with control RNFL thickness and macular volume.
继发性进展性多发性硬化患者平均视网膜神经纤维层的厚度和黄斑面积值亦降低，但与原发性进展性多发性硬化相比不降低。
Objective to research the practical feasibility of autologous stem cell transplantation (ASCT) in the treatment of progressive multiple sclerosis (MS) and its related immunological changes.
目的研究自体造血干细胞移植(ASCT)治疗进展型多发性硬化(MS)临床应用的可行性及免疫学改变。
Most forms of ms are described as progressive.
多数形式的多发性硬化症被描述为前进的。
Most forms of ms are described as progressive.
多数形式的多发性硬化症被描述为前进的。
应用推荐